DNA Biomedical Solutions Ltd.: Entera’s unsuccessful NASDAQ IPO is not expected to have a significant impact on its clinical plans; Price target affected by a change in the exchange rate. jaimeuss_admin 6 בSeptember 2018 Research 0 Comments Continue Reading